On Mar. 27, 1999, Novo Nordisk, the ZymoGenetics parent company, announced approval of NovoSeven by the Food and Drug Administration (FDA) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to coagulation Factors VIII or IX. Seattle based ZymoGenetics was instrumental in the development of NovoSeven(R) Coagulation Factor VIIa (Recombinant), a lifesaving product.

NovoSeven is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors (antibodies) to coagulation Factors VIII or IX. NovoSeven should be administered to patients only under the direct supervision of a physician experienced in the treatment of hemophilia.

Hemophilia is a rare but serious disease. Patients spend their lives at risk of hemorrhage after even minor injury and can experience severe spontaneous bleeding episodes. They may bleed internally or externally and suffer great pain and long-term disability when the bleeding affects their joints or internal organs. Major trauma or surgery will almost inevitably lead to life-threatening hemorrhage.